The oncogenic impacts of the KRAS gene were first reported in the 1980s, making KRAS one of the first identified oncogenes. A KRAS mutation occurs in nearly 30% of human cancers. Also in NSCLC KRAS mutations are often observed. In western populations, KRAS is the most common oncogenic driver mutation in NSCLC, occurring in 30% of patients. In patients with non-small cell lung cancer (NSCLC) that harbor a KRAS mutation, the KRAS G12C sub mutation is seen in 40-45%.
Now that G12C inhibitors are available as a second line of therapy in metastatic NSCLC patients with a KRAS G12C mutation, we aim within this Research Topic to learn more about KRAS and its sub mutations and co-mutations in NSCLC.
This Research Topic will be focused on the progress and controversies in clinical research on KRAS targeting in NSCLC stage IV. We welcome Original Research, Review articles, Perspective and Opinion articles, and unique Case Reports, which are aimed at deepening the translational/biological/genomics/clinical knowledge about patients affected by KRAS mutated NSCLC, exploring epidemiology, diagnosis, prognosis, drug development, and resistance mechanisms.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
The oncogenic impacts of the KRAS gene were first reported in the 1980s, making KRAS one of the first identified oncogenes. A KRAS mutation occurs in nearly 30% of human cancers. Also in NSCLC KRAS mutations are often observed. In western populations, KRAS is the most common oncogenic driver mutation in NSCLC, occurring in 30% of patients. In patients with non-small cell lung cancer (NSCLC) that harbor a KRAS mutation, the KRAS G12C sub mutation is seen in 40-45%.
Now that G12C inhibitors are available as a second line of therapy in metastatic NSCLC patients with a KRAS G12C mutation, we aim within this Research Topic to learn more about KRAS and its sub mutations and co-mutations in NSCLC.
This Research Topic will be focused on the progress and controversies in clinical research on KRAS targeting in NSCLC stage IV. We welcome Original Research, Review articles, Perspective and Opinion articles, and unique Case Reports, which are aimed at deepening the translational/biological/genomics/clinical knowledge about patients affected by KRAS mutated NSCLC, exploring epidemiology, diagnosis, prognosis, drug development, and resistance mechanisms.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
